GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Calidi Biotherapeutics
Shares of Calidi, a biotech company developing oncolytic viruses, reflect the sector's binary risks. The price trajectory depends entirely on the results of clinical trials and regulatory decisions regarding its drugs.
Share prices of companies in the market segment - Cancer cure
Calidi Biotherapeutics is an oncology company developing a platform for delivering oncolytic viruses via stem cells to combat cancer. We've categorized it under "Cancer Treatment." The chart below shows how the market is evaluating innovative virotherapy approaches.
Broad Market Index - GURU.Markets
Calidi Biotherapeutics is a biotech company developing oncolytic viral therapies for cancer treatment. Its innovative approach makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Calidi compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
CLDI - Daily change in the company's share price Calidi Biotherapeutics
Calidi Biotherapeutics, Inc.'s daily price change reflects the extreme volatility inherent in biotech companies. This metric measures sensitivity to news about the clinical trials of its oncolytic viral therapy.
Daily change in the price of a set of shares in a market segment - Cancer cure
Calidi Biotherapeutics develops innovative virus-based platforms to combat cancer. Oncolytic biotechnology is a cutting-edge and highly volatile sector. The chart below shows average daily fluctuations in this industry, serving as a benchmark for assessing the risks and potential of CLDI stock.
Daily change in the price of a broad market stock, index - GURU.Markets
Calidi Biotherapeutics is a biotech company developing oncolytic viruses for cancer treatment. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Calidi Biotherapeutics
For Calidi Biotherapeutics, the year's performance is a story of the development of its unique platform for delivering oncolytic viruses. Its 12-month market cap is entirely dependent on clinical trial data. The success of its approach, which uses stem cells to protect and deliver viruses, could be a breakthrough in the treatment of solid tumors.
Annual dynamics of market capitalization of the market segment - Cancer cure
As an early-stage biotech, Calidi is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news of clinical trials of its oncolytic virotherapy. Its stock price will reflect the speculative faith of investors.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Calidi Biotherapeutics is developing an innovative platform for delivering oncolytic viruses, transforming cancer cells into targets for the immune system. Its year-over-year market capitalization dynamics reflect a bet on a breakthrough in immuno-oncology. The company's success hinges on clinical trial results and could change the paradigm of cancer treatment.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Calidi Biotherapeutics
Calidi is a biotech company developing oncolytic viral therapy. Being in the clinical stage, its monthly valuation is entirely dependent on news. Trial results confirming the viability of its unique platform are the main driver.
Monthly dynamics of market capitalization of the market segment - Cancer cure
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company pioneering the development of oncolytic viruses delivered via stem cells for the treatment of cancer. The dynamics of its sector, shown in the chart, reflect the risks of R&D. Against this backdrop, it is possible to assess the progress of its unique platform, which protects viruses from the immune system, in trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Calidi Biotherapeutics develops cutting-edge cancer therapy using oncolytic viruses. Like most biotech companies, its shares are highly volatile and do not follow the market. Price movements are driven by research data and partnership news. The chart demonstrates how scientific expectations outweigh general economic factors.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Calidi Biotherapeutics
Calidi Biotherapeutics is developing an innovative platform for delivering oncolytic viruses to combat cancer. Its weekly stock price performance reflects investor confidence in this cutting-edge scientific approach. News of clinical trials and partnerships are causing the wild swings typical of biotech.
Weekly dynamics of market capitalization of the market segment - Cancer cure
Calidi Biotherapeutics is developing an innovative platform for delivering oncolytic viruses to combat cancer. This is at the cutting edge of science, and its stock is extremely sensitive to research results. The chart will show whether its price fluctuations are a reaction to the overall market environment or to events unique to the company.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Calidi Biotherapeutics develops cutting-edge cell therapy for cancer. Its stock is a classic biotech, whose performance is 100% dependent on news about trials and FDA decisions. The chart clearly demonstrates this disconnect from the broader market.
Market capitalization of the company, segment and market as a whole
CLDI - Market capitalization of the company Calidi Biotherapeutics
Calidi Biotherapeutics' market capitalization chart reflects investors' bets on its innovative platform for delivering oncolytic viruses. Its dynamics reflect the market's belief that using stem cells to "protect" viruses can more effectively fight cancer. Its value is an estimate of the potential of this new approach in immuno-oncology.
CLDI - Share of the company's market capitalization Calidi Biotherapeutics within the market segment - Cancer cure
Calidi Biotherapeutics is developing an innovative platform for delivering cancer-killing viruses using stem cells. Its market share in the oncology sector is negligible, but it is based on a breakthrough idea. Its capitalization is a bet on its scientific approach, which can overcome the barriers of the immune system.
Market capitalization of the market segment - Cancer cure
This chart shows the total value of the entire oncology sector. For Calidi Biotherapeutics, with its innovative oncolytic virus delivery platform, this line illustrates the scale of the battle against cancer. The rising chart reflects investors' belief that new approaches like the company's platform can "teach" the immune system to recognize and destroy tumors.
Market capitalization of all companies included in a broad market index - GURU.Markets
Calidi Biotherapeutics is developing a platform for delivering oncolytic viruses to combat cancer. Its market capitalization is determined by the innovative "viruses versus cancer" approach. This market share represents the share of the overall market captured by cutting-edge and bold ideas in oncology.
Book value capitalization of the company, segment and market as a whole
CLDI - Book value capitalization of the company Calidi Biotherapeutics
Calidi Biotherapeutics is developing an innovative platform for delivering oncolytic viruses for cancer treatment. Its book value is derived from its scientific and manufacturing base: its own GMP facilities and cash for R&D. How has this foundation for a new generation of therapy grown? The chart below shows.
CLDI - Share of the company's book capitalization Calidi Biotherapeutics within the market segment - Cancer cure
Calidi Biotherapeutics is a cell therapy company developing packaged viruses to fight cancer. Its unique approach requires a sophisticated infrastructure: its own GMP-compliant manufacturing facilities to create its innovative drugs. The chart shows the company's share of the physical infrastructure required for this initiative.
Market segment balance sheet capitalization - Cancer cure
Calidi Biotherapeutics is an oncology company. The pharmaceutical industry, as the chart shows, is both knowledge- and capital-intensive. Calidi focuses on drug development, and its capital lies in its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Calidi Biotherapeutics' book value is not its factories, but rather its laboratories and pilot plant for developing an innovative platform that uses viruses to deliver immunotherapeutic agents directly to tumors. Its assets reflect the material base for this cutting-edge oncology research.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Calidi Biotherapeutics
Calidi Biotherapeutics is an oncology company developing a platform for delivering viruses that kill cancer cells. Its market value is a reflection of its cutting-edge scientific approach. Investors are betting on its ability to transform cancer into a curable disease.
Market to book capitalization ratio in a market segment - Cancer cure
Calidi Biotherapeutics is developing an innovative platform for delivering anti-cancer drugs. Its high valuation on this chart reflects investors' faith in its scientific approach, which could make immunotherapy more effective, despite its early stage of development.
Market to book capitalization ratio for the market as a whole
Calidi Biotherapeutics develops cutting-edge viral cancer treatments. The company's value depends almost entirely on the success of its scientific platform. This chart demonstrates the high premium the market is willing to pay for potentially revolutionary medical technologies, even if their commercialization is still far off.
Debts of the company, segment and market as a whole
CLDI - Company debts Calidi Biotherapeutics
Calidi, a biopharmaceutical company developing an innovative platform for delivering oncolytic viruses for cancer treatment, is in the clinical stage and is entirely dependent on external funding for its research. This chart shows how the company is raising significant capital to test its breakthrough, yet risky, scientific hypothesis.
Market segment debts - Cancer cure
Calidi Biotherapeutics is a clinical-stage biotechnology company developing an innovative platform for delivering oncolytic viruses for cancer treatment. This approach uses viruses to destroy cancer cells. The chart shows how the company is funding the development of its cutting-edge yet complex technology, aiming to overcome barriers to creating a new class of anti-cancer therapies.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Calidi Biotherapeutics
Calidi Biotherapeutics is developing an innovative platform for delivering oncolytic viruses to combat cancer. This is a cutting-edge, but very expensive, area of research. This chart shows how the company leverages its preclinical and clinical programs, reflecting the high financial risks in immuno-oncology.
Market segment debt to market segment book capitalization - Cancer cure
Calidi Biotherapeutics is developing an innovative platform for delivering oncolytic viruses that can destroy cancer cells. This is a cutting-edge but risky field. This chart shows how the company finances its research and development, comparing its debt structure to the overall financial landscape of the biotech sector.
Debt to book value of all companies in the market
Calidi Biotherapeutics is developing an innovative platform for delivering oncolytic viruses that can destroy cancer cells. This is a cutting-edge, but very expensive, area of oncology. How heavily does the company rely on debt financing? This graph of total debt in the economy helps assess the riskiness of its financial model as it seeks success.
P/E of the company, segment and market as a whole
P/E - Calidi Biotherapeutics
Calidi Biotherapeutics is a biopharmaceutical company developing an innovative platform for delivering oncolytic viruses for cancer treatment. This chart shows how investors view its unique approach to immunotherapy. The valuation is dependent on the results of preclinical and clinical trials.
P/E of the market segment - Cancer cure
Calidi Biotherapeutics is a biotech company developing an innovative platform for delivering oncolytic (cancer-killing) viruses via stem cells, thereby protecting them from the immune system. This chart illustrates the average valuation in the cancer cell therapy sector, where investors are betting on breakthrough approaches to cancer treatment.
P/E of the market as a whole
Calidi Biotherapeutics is a biotech company developing an innovative oncolytic virus delivery platform that harnesses the immune system to fight cancer. This chart reflects investors' overall risk appetite. It helps understand whether CLDI's high valuation is based on faith in its unique technology or whether it moves in line with overall biotech sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Calidi Biotherapeutics
Calidi Biotherapeutics is developing an innovative platform for delivering oncolytic (cancer-killing) viruses via stem cells, enhancing their effectiveness. This chart reflects investor confidence in the breakthrough potential of this technology and its potential to revolutionize cancer immunotherapy, which drives future revenue expectations.
%20P%2FE%20Calidi%20Biotherapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Calidi-Biotherapeutics&v=1772554035780 "Chart of the company's future (projected) P/E Calidi Biotherapeutics")
Future (projected) P/E of the market segment - Cancer cure
Calidi Biotherapeutics is developing an innovative platform for delivering oncolytic viruses that can destroy cancer cells. This represents the cutting edge of cancer treatment. The chart reflects the sector's future profit expectations, helping to understand how high investor expectations are for Calidi's technology to become a breakthrough in oncology.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772554035823 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
Calidi Biotherapeutics is developing an innovative platform for delivering oncolytic viruses that can destroy cancer cells. This is a cutting-edge approach in immuno-oncology. This risk appetite chart is an indicator of the market's willingness to fund breakthrough, but high-risk, technologies in the fight against cancer.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772554035836 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Calidi Biotherapeutics
Calidi Biotherapeutics is developing an innovative platform for delivering oncolytic (cancer-killing) viruses via stem cells, which should improve the effectiveness of therapy. Financial indicators reflect R&D expenditures. This chart shows investments in a cutting-edge cancer treatment that could revolutionize oncology and generate future profits for the company.
Profit of companies in the market segment - Cancer cure
Calidi Biotherapeutics is developing an innovative platform for delivering oncolytic (cancer-killing) viruses via stem cells, which should improve the efficacy and safety of therapy. This chart shows the overall profitability of the cancer treatment sector, where cell and viral therapies are among the most promising and rapidly growing areas.
Overall market profit
Calidi Biotherapeutics develops innovative virus-based cancer immunotherapies. The company is at the forefront of biotechnology. Its value and future are determined by the success of clinical trials, not the current economic situation. The dynamics in this chart do not affect the demand for breakthrough cancer treatments.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Calidi Biotherapeutics
Calidi Biotherapeutics is developing an innovative platform for delivering oncolytic (cancer-killing) viruses via stem cells, thereby protecting them from the immune system. Future profits depend on the success of this cutting-edge technology in the clinic. This chart reflects analysts' speculative forecasts for the future of cell therapy in oncology.
%20profit%20of%20the%20company%20Calidi%20Biotherapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Calidi-Biotherapeutics&v=1772554036166 "Graph of future (projected) profit of the company Calidi Biotherapeutics")
Future (predicted) profit of companies in the market segment - Cancer cure
Calidi Biotherapeutics is developing an innovative platform for delivering oncolytic (cancer-killing) viruses via stem cells, which should improve treatment effectiveness. The company's future depends on the success of its clinical programs. This chart shows revenue projections for the oncology sector, helping to assess the potential of Calidi's cutting-edge technology.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772554036196 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
Calidi Biotherapeutics develops innovative platforms for delivering oncolytic viruses for cancer treatment. The company's future depends on the success of clinical trials and raising capital. This revenue expectation schedule impacts investor risk appetite, which is critical for funding cutting-edge biotech companies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772554036245 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Calidi Biotherapeutics
Calidi Biotherapeutics is developing an innovative platform for delivering oncolytic viruses to combat cancer. There is currently no revenue. This chart is an indicator of investor confidence in its unique scientific approach. Any movement on it reflects clinical trial progress, not financial results.
P/S market segment - Cancer cure
Calidi Biotherapeutics is a pioneer in the development of oncolytic virotherapy—an innovative approach to cancer treatment that uses viruses to destroy tumor cells and stimulate the immune system. This chart shows the average revenue estimate for the sector, providing insight into the market's expectations for this cutting-edge oncology field.
P/S of the market as a whole
Calidi Biotherapeutics is a biotech company developing an innovative platform for delivering oncolytic viruses to combat cancer. This chart highlights that the valuation of such companies is based on investor confidence in the breakthrough nature of their scientific platform, rather than on current financial performance, which significantly distinguishes them from the market average.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Calidi Biotherapeutics
Calidi Biotherapeutics is developing an innovative platform for delivering oncolytic viruses for cancer treatment using stem cells. For a clinical-stage biotech company, future revenue estimates are critical. They reflect investors' confidence in the breakthrough potential of its technology and the future commercial success of its anti-cancer therapies if approved.
%20P%2FS%20Calidi%20Biotherapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Calidi-Biotherapeutics&v=1772554036488 "The graph of the company's future (projected) P/S Calidi Biotherapeutics")
Future (projected) P/S of the market segment - Cancer cure
Calidi Biotherapeutics develops oncolytic virotherapy—an innovative approach to cancer treatment that uses viruses to destroy tumor cells. This chart compares the company's estimated future sales with expectations for the biotech sector. It shows how investors view the potential of its platform for creating next-generation anticancer drugs.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772554036493 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
Calidi Biotherapeutics is developing an innovative platform that uses viruses to deliver and enhance the action of stem cells in cancer treatment. The company's future depends on the success of this cutting-edge technology in the clinic. This market outlook chart reflects investor confidence in cell and viral therapies as the next generation of oncology treatments.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772554036543 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Calidi Biotherapeutics
This chart illustrates the financial performance of Calidi Biotherapeutics, a biotech company developing innovative immunotherapy platforms for cancer treatment. Being in clinical trials, the company may not have stable sales revenue. This indicator reflects revenue from partnerships or grants aimed at developing its technologies.
Sales of companies in the market segment - Cancer cure
Calidi Biotherapeutics is developing an innovative platform for delivering oncolytic viruses that can destroy cancer cells. Currently in the clinical stage, the company has no sales revenue yet. Its future revenue will depend on the successful commercialization of this cutting-edge technology for the treatment of solid tumors.
Overall market sales
Calidi Biotherapeutics develops innovative platforms for delivering oncolytic viruses, transforming them into powerful weapons against cancer. The company is at the forefront of immunotherapy. This general economic chart does not apply to Calidi's prospects, which are determined solely by scientific breakthroughs and clinical trial results in the fight against cancer.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Calidi Biotherapeutics
Calidi Biotherapeutics is developing an innovative platform for delivering oncolytic (cancer-killing) viruses that utilizes stem cells to protect the virus from the immune system and deliver it to the tumor. Future revenues are dependent on the success of clinical trials. This chart reflects analyst projections for the potential of this new technology in treating solid tumors.
%20sales%20of%20the%20company%20Calidi%20Biotherapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Calidi-Biotherapeutics&v=1772554036839 "Schedule of future (projected) sales of the company Calidi Biotherapeutics")
Future (projected) sales of companies in the market segment - Cancer cure
Calidi Biotherapeutics develops innovative virus-based platforms for delivering immunotherapy directly to tumors. This chart shows the forecast for the oncology sector. Is a breakthrough in oncolytic viruses expected to spur growth of the entire market? This allows us to assess the overall scientific and commercial potential of the industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772554036870 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
Calidi Biotherapeutics develops innovative platforms for delivering oncolytic viruses for cancer treatment. The company's success depends on scientific breakthroughs, clinical trial results, and partnerships with major pharmaceutical companies. This chart, which reflects general economic trends, does not reflect the fundamental drivers of this cutting-edge biotech business.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772554036879 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Calidi Biotherapeutics
Calidi Biotherapeutics is developing an innovative platform for delivering oncolytic viruses that can destroy cancer cells. This chart shows the company's financial performance at the clinical trial stage. Profitability is a future goal and will depend on the success of its unique approach, which could significantly improve the effectiveness of viral cancer therapy.
Market segment marginality - Cancer cure
Calidi Biotherapeutics is a clinical-stage biotechnology company developing an innovative platform for delivering oncolytic viruses for cancer treatment. This chart depicts the company's financial performance, whose future profitability depends on the success of its unique approach in clinical trials and potential partnerships with major pharmaceutical companies.
Market marginality as a whole
Calidi Biotherapeutics develops innovative platforms for delivering oncolytic viruses, transforming cancer cells into targets for the immune system. The company is at the forefront of science. This total return chart reflects the investment appetite for risky but potentially breakthrough biotech companies.
Employees in the company, segment and market as a whole
Number of employees in the company Calidi Biotherapeutics
Calidi Biotherapeutics is developing an innovative platform for delivering oncolytic viruses to combat cancer. Its team of scientists and clinicians is its greatest asset. This chart shows how the biotech startup is growing its team to advance its developments through preclinical and early clinical trials, a critical stage.
Share of the company's employees Calidi Biotherapeutics within the market segment - Cancer cure
Calidi Biotherapeutics is developing an innovative platform for delivering oncolytic viruses to combat cancer. This is a cutting-edge field of biotechnology, requiring a team of highly qualified virologists, immunologists, and cell therapy specialists. This chart shows the company's market share, reflecting its scientific potential and the scale of its R&D in this promising field.
Number of employees in the market segment - Cancer cure
Calidi Biotherapeutics develops oncolytic virotherapy—a cancer treatment method using modified viruses that infect and destroy cancer cells. This chart shows employment in the oncology sector. Calidi's platform, which uses stem cells to deliver viruses, represents a cutting-edge approach in immuno-oncology.
Number of employees in the market as a whole
Calidi Biotherapeutics develops innovative platforms for delivering oncolytic viruses to fight cancer. It is at the forefront of immunotherapy. The company's growth is driven by scientific advances. Against the backdrop of the overall job market picture shown in this chart, Calidi represents the world of biotech, where jobs are being created to revolutionize cancer treatment.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Calidi Biotherapeutics (CLDI)
Calidi Biotherapeutics develops cutting-edge cancer treatments using oncolytic viruses. This is one of the most complex areas of biotech. This chart shows the enormous market premium placed on their scientific platform. It reflects the market value per scientist, a direct indicator of the anticipation of breakthroughs in cancer treatment.
%20of%20the%20company%20Calidi%20Biotherapeutics%20(CLDI)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Calidi-Biotherapeutics-CLDI&v=1772554037594 "Chart of market capitalization per employee (in thousands of dollars) of the company Calidi Biotherapeutics (CLDI)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
Calidi Biotherapeutics (CLDI) is developing an innovative platform for delivering oncolytic viruses to combat cancer. In advanced oncology, the company's valuation per employee is a pure reflection of scientific excellence. This astronomically high figure could indicate that the company's technology is capable of transforming cancer cells into tumor-fighting "factories," the holy grail of therapeutics.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772554037661 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
Calidi Biotherapeutics is developing an innovative platform for delivering oncolytic viruses for cancer treatment. The company's value lies in its scientific platform. The chart shows a high valuation per employee, as the market sees enormous potential in this new approach to cancer immunotherapy, which could overcome the limitations of existing methods.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772554037751 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Calidi Biotherapeutics (CLDI)
Calidi Biotherapeutics is a biotechnology company developing oncolytic viral therapies (for cancer treatment). This is a cutting-edge R&D company. This graph shows the investment phase. The loss per employee here means that each scientist is a cost center, funded by investors to create a breakthrough cancer treatment technology.
%20Chart%20Calidi%20Biotherapeutics%20(CLDI)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Calidi-Biotherapeutics-CLDI&v=1772554037906 "Company Profit Per Employee (in thousands of dollars) Chart Calidi Biotherapeutics (CLDI)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
Calidi Biotherapeutics develops innovative viral-based cancer immunotherapy methods. For companies at the forefront of science, effectiveness is measured not by the number of employees, but by the quality of their discoveries. This chart shows the financial return per scientist, which is a leading indicator of the commercial potential of their platform compared to other biotech startups.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772554037985 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
Calidi Biotherapeutics is a biotech company developing oncolytic viruses (viruses that kill cancer) to treat tumors. This is cutting-edge cell therapy. Their business is pure science and R&D. This chart, showing average market performance, helps to understand the contrast with biotech, where a team of scientists burns through capital in hopes of a breakthrough.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772554038036 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Calidi Biotherapeutics (CLDI)
Calidi Biotherapeutics develops innovative platforms for delivering oncolytic viruses to combat cancer. During the R&D phase, revenue per employee can be zero. This graph is a glimpse into the future: if successful, their technology could generate billions, making this figure astronomical and reflecting the value of their science.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Calidi-Biotherapeutics-CLDI&v=1772554038100 "Sales chart per company employee Calidi Biotherapeutics (CLDI)")
Sales per employee in the market segment - Cancer cure
Calidi Biotherapeutics is a clinical-stage biotech company developing oncolytic viral platforms (using viruses to fight cancer). They have no commercial revenue. This chart, showing the average revenue per employee in the sector, serves as a cost-effectiveness barometer for Calidi. It reflects how expensive their R&D staff is compared to their biotech competitors.
Sales per employee for the market as a whole
Calidi Biotherapeutics is a biotech company developing cutting-edge oncolytic viruses (viruses that kill cancer) for the treatment of tumors. Their business is at the cutting edge of science. This chart reflects their R&D status: the company is in clinical trials and does not yet generate commercial revenue from its cell therapies.
Short shares by company, segment and market as a whole
Shares shorted by company Calidi Biotherapeutics (CLDI)
Calidi (CLDI) is developing a platform for delivering oncolytic (cancer-killing) viruses using stem cells. This is cutting-edge, but highly risky, science. This chart shows the number of short positions. The bears are betting that this complex technology will not prove safe and effective in human clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Calidi-Biotherapeutics-CLDI&v=1772554038214 "Short Shares Chart for the Company Calidi Biotherapeutics (CLDI)")
Shares shorted by market segment - Cancer cure
Calidi Biotherapeutics (CLDI) is a biotech company developing oncolytic viral therapies (viruses that kill cancer) using a "virus-in-a-cell" platform. This chart aggregates short positions across the entire oncology biotech sector. It reflects general investor skepticism regarding the risks of clinical trials and the complexities of cell therapy.
Shares shorted by the overall market
Calidi (CLDI) is a clinical-stage biotech. Its value reflects the hope for future success. When this indicator of overall pessimism rises, investors are less inclined to hope. They are dumping unprofitable companies en masse, requiring refinancing.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Calidi Biotherapeutics (CLDI)
Calidi Biotherapeutics (CLDI) is a biotech company that uses oncolytic viruses (which kill cancer) in combination with stem cells to enhance their effectiveness. This oscillator measures the strength of speculative moves. It shows when the stock is "overheated" (above 70) on trial news or "oversold" (below 30) due to profit-taking.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Calidi-Biotherapeutics-CLDI&v=1772554038325 "RSI 14 indicator chart for the company's stock Calidi Biotherapeutics (CLDI)")
RSI 14 Market Segment - Cancer cure
Calidi Biotherapeutics is a biopharmaceutical company developing "oncolytic virotherapy" (using viruses to kill cancer) protected by stem cells. This chart shows the overall "temperature" in the volatile oncology biotech sector. It helps separate CLDI's dynamics from the general "hype" or "disappointment" sweeping the industry.
RSI 14 for the overall market
Calidi Biotherapeutics (CLDI) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CLDI (Calidi Biotherapeutics)
Calidi Biotherapeutics is a biotech company developing a groundbreaking platform that uses stem cells to "protect" and deliver oncolytic (cancer-killing) viruses directly to tumors. This chart shows the speculative average price target from analysts based on their belief in this cutting-edge R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CLDI-Calidi-Biotherapeutics&v=1772554038529 "A chart showing analyst consensus forecasts for the expected stock price. CLDI (Calidi Biotherapeutics)")
The difference between the consensus estimate and the actual stock price CLDI (Calidi Biotherapeutics)
Calidi is a biotech company that "weapons" viruses (oncolytic virotherapy) to attack cancer tumors from within, using stem cells as a "shield." This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their faith in this cutting-edge R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CLDI-Calidi-Biotherapeutics&v=1772554038557 "A chart showing the difference between the consensus forecast and the actual stock price. CLDI (Calidi Biotherapeutics)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
Calidi (CLDI) is a biotech company developing a sophisticated platform for "packaging" cancer-killing viruses into stem cells to protect them from the immune system. This is risky R&D. This chart shows analysts' overall expectations for the entire oncology cell therapy sector. It reflects whether experts believe this technology will achieve breakthroughs or whether the sector faces a "funding winter."
Analysts' consensus forecast for the overall market share price
Calidi Biotherapeutics is a biotech company developing oncolytic (cancer-killing) viruses that are delivered to tumors using stem cells. This is a high-risk sector, where success depends on the results of clinical trials. This chart reflects the overall risk appetite in the market. For Calidi, which has yet to generate revenue, the overall analyst optimism (the rising chart) is critical for raising capital.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Calidi Biotherapeutics
Calidi is a biotech R&D company working at the forefront of oncology. Their signature platform uses stem cells as a shield to smuggle oncolytic (cancer-killing) viruses directly into tumors. This chart is a clear indicator of their faith in R&D. It doesn't reflect revenue, but rather the market's speculative valuation of their (very risky) pipeline and their clinical trial data.
AKIMA Market Segment Index - Cancer cure
Calidi Biotherapeutics (CLDI) uses a Trojan horse strategy in oncology. Their platform (NeuroNova, Vax-On) arms stem cells with oncolytic viruses, which are then delivered directly to the tumor to attack the cancer from within and activate the immune system. This chart shows the segment's average index, helping investors assess how this cutting-edge but risky technology compares to the average.
The AKIM Index for the overall market
Calidi Biotherapeutics is a biotech company that uses stem cells as "Trojan horses" to deliver oncolytic viruses to tumors. This chart, which reflects the market average, is an indicator of risk appetite. It reveals the macro backdrop critical to funding this innovative platform.
